Heart failure & cardiomyopathies
Dose Titration of Sacubitril/Valsartan for Heart Failure with Reduced Ejection Fraction: A Real-World Study
Authors' conclusion
Optimising HF follow-up management was essential and effective in a real-world clinical setting; the majority could reach the target dose of sacubitril/valsartan within the management system and achieve a remarkable improvement in cardiac function and ventricular remodelling.
Study context
- Population
- Adult outpatients with HFrEF in a chronic heart failure (HF) follow-up management system prescribed sacubitril/valsartan, China, August 2017–August 2021
- Participants
- 153 outpatients
- Outcome
- Proportion of patients who reached and maintained the target dose of sacubitril/valsartan
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Patients achieving target dose
117
76.5%
Median time to target dose
3 (IQR 1-5) months
Observational data: associations, not effects.
Secondary outcomes
Left ventricular ejection fraction (LVEF), baseline vs 12 months
- LVEF baseline vs 12 months (median)
- 28 (IQR 21-34) % vs. 42 (IQR 37.0-54.3) %, P < 0.001
Left atrium diameter, baseline vs 12 months
- Left atrium diameter baseline vs 12 months (median)
- 45 (IQR 40.3-51.0) mm vs. 41 (IQR 37.0-45.3) mm, P < 0.001
Left ventricular end-diastolic diameter (LVEDD), baseline vs 12 months
- LVEDD baseline vs 12 months (median)
- 65 (IQR 60.0-70.3) mm vs. 55 (IQR 52-62) mm, P < 0.001
LVEF categories · 12 months
- LVEF ≥50%
- 36.5%
- LVEF >40%
- 54.1%
- LVEF increase ≥10%
- 81.1%
NYHA class I or II · 12 months
- Proportion NYHA I or II, baseline vs 12 months
- 41.8% to 96.4%
NT-proBNP
- Significant improvement
- P < 0.001
Target dose of beta-blockers · Month 12
- Achieved target beta-blocker dose
- 50%
Safety
Serious adverse events caused by sacubitril/valsartan
- No serious adverse events observed
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →